Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.

Tembuyser L, Ligtenberg MJ, Normanno N, Delen S, van Krieken JH, Dequeker EM.

J Mol Diagn. 2014 May;16(3):371-7. doi: 10.1016/j.jmoldx.2014.01.003. Epub 2014 Mar 14.

PMID:
24631467
2.

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.

Tack V, Ligtenberg MJ, Tembuyser L, Normanno N, Vander Borght S, Han van Krieken J, Dequeker EM.

Oncologist. 2015 Mar;20(3):257-62. doi: 10.1634/theoncologist.2014-0382. Epub 2015 Feb 5.

3.

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.

Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjö A, Gorgoulis V, Höfler G, Jung A, Kotsinas A, Laurent-Puig P, López-Ríos F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E.

Oncologist. 2011;16(4):467-78. doi: 10.1634/theoncologist.2010-0429. Epub 2011 Mar 26.

4.

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.

Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC.

Mod Pathol. 2011 Aug;24(8):1090-100. doi: 10.1038/modpathol.2011.60. Epub 2011 Apr 22.

5.

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.

Normanno N, Pinto C, Castiglione F, Fenizia F, Barberis M, Marchetti A, Fontanini G, De Rosa G, Taddei GL.

J Transl Med. 2015 Sep 3;13:287. doi: 10.1186/s12967-015-0655-1.

6.

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.

Feigelson HS, Goddard KA, Johnson MA, Funk KC, Rahm AK, Kauffman TL, Chitale DA, Le Marchand L, Richards CS.

BMC Res Notes. 2012 Apr 25;5:196. doi: 10.1186/1756-0500-5-196.

7.

Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.

Dijkstra JR, Opdam FJ, Boonyaratanakornkit J, Schönbrunner ER, Shahbazian M, Edsjö A, Hoefler G, Jung A, Kotsinas A, Gorgoulis VG, López-Ríos F, de Stricker K, Rouleau E, Biesmans B, van Krieken JH.

J Mol Diagn. 2012 May-Jun;14(3):187-91. doi: 10.1016/j.jmoldx.2012.01.002. Epub 2012 Mar 10.

PMID:
22414609
8.

Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective.

Ross JS.

Arch Pathol Lab Med. 2012 Oct;136(10):1298-307. Epub 2012 Jan 24. Review.

PMID:
22272560
9.

Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.

Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P; MOKAECM Collaborative Group.

PLoS One. 2013 Jul 25;8(7):e68945. doi: 10.1371/journal.pone.0068945. Print 2013.

10.

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.

Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J.

Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620. Review.

11.

Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.

Ausch C, Buxhofer-Ausch V, Oberkanins C, Holzer B, Minai-Pour M, Jahn S, Dandachi N, Zeillinger R, Kriegshäuser G.

J Mol Diagn. 2009 Nov;11(6):508-13. doi: 10.2353/jmoldx.2009.090022. Epub 2009 Oct 1.

12.

KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.

Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R, Salto-Tellez M.

Cytopathology. 2011 Dec;22(6):358-64. doi: 10.1111/j.1365-2303.2010.00812.x. Epub 2010 Oct 4.

PMID:
21029218
13.

KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues.

Solassol J, Ramos J, Crapez E, Saifi M, Mangé A, Vianès E, Lamy PJ, Costes V, Maudelonde T.

Int J Mol Sci. 2011;12(5):3191-204. doi: 10.3390/ijms12053191. Epub 2011 May 17.

14.

The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.

Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, Oka M, Hinoda Y.

Jpn J Clin Oncol. 2011 Feb;41(2):165-71. doi: 10.1093/jjco/hyq173. Epub 2010 Oct 5.

PMID:
20926413
15.

Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.

Chretien AS, Harlé A, Meyer-Lefebvre M, Rouyer M, Husson M, Ramacci C, Harter V, Genin P, Leroux A, Merlin JL.

Cancer Med. 2013 Feb;2(1):11-20. doi: 10.1002/cam4.47. Epub 2013 Feb 3.

16.

Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer.

Kristensen LS, Kjeldsen TE, Hager H, Hansen LL.

BMC Cancer. 2012 Nov 23;12:548. doi: 10.1186/1471-2407-12-548.

17.

Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.

Laosinchai-Wolf W, Ye F, Tran V, Yang Z, White R, Bloom K, Choppa P, Labourier E.

J Clin Pathol. 2011 Jan;64(1):30-6. doi: 10.1136/jcp.2010.081539. Epub 2010 Oct 28.

PMID:
21030527
18.

KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.

Dijkstra JR, Heideman DA, Meijer GA, Boers JE, 't Hart NA, Diebold J, Hirschmann A, Hoefler G, Winter G, Miltenberger-Miltenyi G, Pereira SV, Richman SD, Quirke P, Rouleau EL, Guinebretiere JM, Tejpar S, Biesmans B, van Krieken JH.

Virchows Arch. 2013 Jan;462(1):39-46. doi: 10.1007/s00428-012-1356-2. Epub 2012 Dec 15.

PMID:
23242173
19.

Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.

Hoorens A, Jouret-Mourin A, Sempoux C, Demetter P, De Hertogh G, Teugels E.

Acta Gastroenterol Belg. 2010 Oct-Dec;73(4):497-503. Review.

PMID:
21299161
20.

KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, Stenzinger A, Joos H, Landt O, Heiser V, Röcken C, Dietel M.

J Mol Diagn. 2010 Jan;12(1):35-42. doi: 10.2353/jmoldx.2010.090079. Epub 2009 Dec 10.

Supplemental Content

Support Center